Systematic Financial Management LP Has $48.03 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Systematic Financial Management LP has increased its stake in Jazz Pharmaceuticals by 2.8% in Q1, making it the fund's 9th largest position, holding 386,903 shares valued at approximately $48 million.
• CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock, reducing his holdings by 0.23% to approximately $47 million after the transaction.
• Jazz Pharmaceuticals reported an EPS loss of ($8.25) for the latest quarter, missing expectations, while its revenue was reported at $1.05 billion, reflecting a 2.1% year-over-year increase.

Systematic Financial Management LP boosted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 2.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 386,903 shares of the specialty pharmaceutical company's stock after purchasing an additional 10,590 shares during the period. Jazz Pharmaceuticals accounts for approximately 1.4% of Systematic Financial Management LP's portfolio, making the stock its 9th biggest position. Systematic Financial Management LP owned about 0.63% of Jazz Pharmaceuticals worth $48,034,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Jump Financial LLC bought a new position in Jazz Pharmaceuticals during the first quarter valued at about $550,000. SVB Wealth LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter worth about $36,000. Northwestern Mutual Wealth Management Co. boosted its holdings in Jazz Pharmaceuticals by 21.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 3,434 shares of the specialty pharmaceutical company's stock valued at $426,000 after purchasing an additional 606 shares in the last quarter. Martingale Asset Management L P boosted its holdings in Jazz Pharmaceuticals by 116.8% during the first quarter. Martingale Asset Management L P now owns 8,641 shares of the specialty pharmaceutical company's stock valued at $1,073,000 after purchasing an additional 4,656 shares in the last quarter. Finally, Groupama Asset Managment boosted its holdings in Jazz Pharmaceuticals by 7.6% during the first quarter. Groupama Asset Managment now owns 8,718 shares of the specialty pharmaceutical company's stock valued at $1,072,000 after purchasing an additional 619 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of research analyst reports. Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Robert W. Baird cut their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Morgan Stanley cut their price objective on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price objective for the company. Finally, Royal Bank Of Canada cut their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $181.43.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Trading Up 1.2%

NASDAQ:JAZZ traded up $1.48 during trading hours on Monday, hitting $124.59. 1,011,665 shares of the stock were exchanged, compared to its average volume of 842,579. The company's 50 day moving average is $113.03 and its two-hundred day moving average is $117.13. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $7.56 billion, a P/E ratio of -18.51, a price-to-earnings-growth ratio of 7.76 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the company posted $5.30 EPS. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.